Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta

Executive Summary

With Super Bowl mania rampant, what are the chances of the biopharmaceutical industry’s equivalent: a mega-merger within big pharma? A Wall Street analyst downplays the likelihood of another Pfizer/Wyeth-like pairing, but raises the possibility that industry will see a mid-sized deal intended to mimic the success of the Sanofi/Genzyme merger.


Related Content

Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief
RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year
Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over
Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014
Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs
BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On
Merck/Schering: The Next Wave Of Consolidation
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts